Beyond the ligand-binding pocket: Targeting alternate sites in nuclear receptors

Medicinal Research Reviews

Volumn 33, Issue 5, 2013, Pages 1081-1118

  Caboni, Laura ^a   Lloyd, David G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alternative site; Non LBP; Nuclear receptor

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CELL NUCLEUS RECEPTOR; COUMESTROL; DNA TOPOISOMERASE INHIBITOR; ENZALUTAMIDE; EPI 001; ESTROGEN RECEPTOR; FLUFENAMIC ACID; FULVESTRANT; GLUCOCORTICOID RECEPTOR; GOSSYPOL; KETOCONAZOLE; LEFLUNOMIDE; MECLOFENAMIC ACID; NIPHATENONE A; NIPHATENONE B; OXICONAZOLE; PHENOL DERIVATIVE; PREGNANE X RECEPTOR; RIFAMPICIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SERTACONAZOLE; TAMOXIFEN; TOLFENAMIC ACID; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; XR 5944;

AMINO ACID SEQUENCE; ANTIANDROGEN THERAPY; ARTICLE; BINDING SITE; BONE MINERALIZATION; BREAST CANCER; BREAST METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CELL MEMBRANE PERMEABILITY; CHROMATIN IMMUNOPRECIPITATION; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CROSS REACTION; CRYSTAL STRUCTURE; CYCLIZATION; DEAMINATION; DIMERIZATION; DNA RESPONSIVE ELEMENT; DNA SEQUENCE; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; ENVIRONMENTAL FACTOR; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SCREENING; HORMONE RESPONSIVE ELEMENT; HUMAN; HYDROPHOBICITY; HYPERTHYROIDISM; IN VITRO STUDY; LIGAND BINDING; LIPOPHILICITY; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PAGET BONE DISEASE; PHAGE DISPLAY; PHARMACOPHORE; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; THYROID GLAND; TRANSACTIVATION; TRANSCRIPTION INITIATION; X RAY CRYSTALLOGRAPHY;

ALTERNATIVE SITE; NON-LBP; NUCLEAR RECEPTOR;

ALLOSTERIC SITE; ANIMALS; BINDING SITES; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84881229056     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21275     Document Type: Article

References (160)

1. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3(11):950-964.
2. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5(10):821-834.
3. Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006;58(4):685-704.
4. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 1999;274(52):37219-37225.
5. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006;25(51):6868-6886.
6. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 1991;352(6335):497-505.
7. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2004;2(9):E274.
8. MOE 2011.10. Montreal: Chemical Computing Group. www.chemcomp.com; 2011.
9. Mohla S, Stearns V, Sathyamoorthy N, Rosenfeld MG, Nelson P. The biology of hormone refractory breast and prostate cancer: An NCI workshop report. Cancer Biol Ther 2009;8(21):1975-1985.
10. Estebanez-Perpina E, Jouravel N, Fletterick RJ. Perspectives on designs of antiandrogens for prostate cancer. Expert Opin Drug Discov 2007;2(10):1341-1355.
11. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-790.
12. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010;375(9724):1437-1446.
13. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13):1187-1197.
14. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51(15):3867-3873.
15. Morris C, Wakeling A. Fulvestrant ('Faslodex')-A new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002;9(4):267-276.
16. Chang CY, McDonnell DP. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 2005;26(5):225-228.
17. Moore TW, Mayne CG, Katzenellenbogen JA. Minireview: Not picking pockets: Nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 2009;24(4):683-695.
18. Shapiro DJ, Mao C, Cherian MT. Small molecule inhibitors as probes for estrogen and androgen receptor action. J Biol Chem 2011;286(6):4043-4048.
19. Vaz B, Mocklinghoff S, Brunsveld L. Targeting the nuclear receptor-cofactor interaction. In: Ottow E, Weinmann H, Eds. Nuclear Receptors as Drug Targets, Methods and Principles in Medicinal Chemistry. Wiley-VCH; 2008. p 25-45.
20. van de Wijngaart DJ, Dubbink HJ, van Royen ME, Trapman J, Jenster G. Androgen receptor coregulators: Recruitment via the coactivator binding groove. Mol Cell Endocrinol 2012;352(1-2):57-69.
21. Gao W. Peptide antagonist of the androgen receptor. Curr Pharm Des 2010;16(9):1106-1113.
22. Estebanez-Perpina E, Fletterick, RJ. The androgen receptor coactivator-binding interface. In: Tindall D, Mohler J, Eds. Androgen Action in Prostate Cancer. Springer; 2009. p 297-311.
23. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat Rev Drug Discov 2004;3(4):301-317.
24. Kong EH, Heldring N, Gustafsson JA, Treuter E, Hubbard RE, Pike AC. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proc Natl Acad Sci USA 2005;102(10):3593-3598.
25. Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev 2007;28(5):575-587.
26. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95(7):927-937.
27. Mocklinghoff S, Rose R, Carraz M, Visser A, Ottmann C, Brunsveld L. Synthesis and crystal structure of a phosphorylated estrogen receptor ligand binding domain. Chembiochem 2010;11(16):2251-2254.
28. Estebanez-Perpina E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD, Buehrer BM, Webb P, Fletterick RJ, Guy RK. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 2005;280(9):8060-8068.
29. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S, Schafer M, Egner U, Carrondo MA. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000;275(34):26164-26171.
30. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002;110(1):93-105.
31. Hsieh RW, Rajan SS, Sharma SK, Greene GL. Molecular characterization of a B-ring unsaturated estrogen: Implications for conjugated equine estrogen components of premarin. Steroids 2008;73(1):59-68.
32. He B, Minges JT, Lee LW, Wilson EM. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 2002;277(12):10226-10235.
33. Hsu CL, Chen YL, Yeh S, Ting HJ, Hu YC, Lin H, Wang X, Chang C. The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. J Biol Chem 2003;278(26):23691-23698.
34. He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 2000;275(30):22986-22994.
35. He B, Gampe RT, Jr, Kole AJ, Hnat AT, Stanley TB, An G, Stewart EL, Kalman RI, Minges JT, Wilson EM. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004;16(3):425-438.
36. Dubbink HJ, Hersmus R, Verma CS, van der Korput HA, Berrevoets CA, van Tol J, Ziel-van der Made AC, Brinkmann AO, Pike AC, Trapman J. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol Endocrinol 2004;18(9):2132-2150.
37. Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, O'Malley BW. Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol 2011;25(12):2041-2053.
38. Sadar MD. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res 2011;71(4):1208-1213.
39. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991;5(10):1396-1404.
40. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;266(1):510-518.
41. Rundlett SE, Wu XP, Miesfeld RL. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 1990;4(5):708-714.
42. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP. Peptide antagonists of the human estrogen receptor. Science 1999;285(5428):744-746.
43. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA 1999;96(7):3999-4004.
44. Chang C, Norris JD, Gron H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: Discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol 1999;19(12):8226-8239.
45. Hall JM, Chang CY, McDonnell DP. Development of peptide antagonists that target estrogen receptor beta-coactivator interactions. Mol Endocrinol 2000;14(12):2010-2023.
46. Mettu NB, Stanley TB, Dwyer MA, Jansen MS, Allen JE, Hall JM, McDonnell DP. The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Mol Endocrinol 2007;21(10):2361-2377.
47. Yang J, Chang CY, Safi R, Morgan J, McDonnell DP, Fuller PJ, Clyne CD, Young MJ. Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display. Mol Endocrinol 2011;25(1):32-43.
48. Northrop JP, Nguyen D, Piplani S, Olivan SE, Kwan ST, Go NF, Hart CP, Schatz PJ. Selection of estrogen receptor beta- and thyroid hormone receptor beta-specific coactivator-mimetic peptides using recombinant peptide libraries. Mol Endocrinol 2000;14(5):605-622.
49. Chang CY, McDonnell DP. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 2002;16(4):647-660.
50. Chang CY, Abdo J, Hartney T, McDonnell DP. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 2005;19(10):2478-2490.
51. van de Wijngaart DJ, van Royen ME, Hersmus R, Pike AC, Houtsmuller AB, Jenster G, Trapman J, Dubbink HJ. Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain. J Biol Chem 2006;281(28):19407-19416.
52. Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, Chang HC, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C. Modulation of androgen receptor transactivation by gelsolin: A newly identified androgen receptor coregulator. Cancer Res 2003;63(16):4888-4894.
53. van de Wijngaart DJ, Dubbink HJ, Molier M, de Vos C, Jenster G, Trapman J. Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell-penetrating peptides, and lentiviral infection. Prostate 2011;71(3):241-253.
54. Joseph JD, Wittmann BM, Dwyer MA, Cui H, Dye DA, McDonnell DP, Norris JD. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci USA 2009;106(29):12178-12183.
55. Steketee K, Berrevoets CA, Dubbink HJ, Doesburg P, Hersmus R, Brinkmann AO, Trapman J. Amino acids 3-13 and amino acids in and flanking the 23FxxLF27 motif modulate the interaction between the N-terminal and ligand-binding domain of the androgen receptor. Eur J Biochem 2002;269(23):5780-5791.
56. Dubbink HJ, Hersmus R, Pike AC, Molier M, Brinkmann AO, Jenster G, Trapman J. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping. Mol Endocrinol 2006;20(8):1742-1755.
57. Vaz B, Mocklinghoff S, Folkertsma S, Lusher S, de Vlieg J, Brunsveld L. Computational design, synthesis, and evaluation of miniproteins as androgen receptor coactivator mimics. Chem Commun (Camb) 2009; (36):5377-5379.
58. Phan T, Nguyen HD, Goksel H, Mocklinghoff S, Brunsveld L. Phage display selection of miniprotein binders of the estrogen receptor. Chem Commun (Camb) 2010;46(43):8207-8209.
59. Kurebayashi S, Nakajima T, Kim SC, Chang CY, McDonnell DP, Renaud JP, Jetten AM. Selective LXXLL peptides antagonize transcriptional activation by the retinoid-related orphan receptor RORgamma. Biochem Biophys Res Commun 2004;315(4):919-927.
60. Pathrose P, Barmina O, Chang CY, McDonnell DP, Shevde NK, Pike JW. Inhibition of 1, 25-dihydroxyvitamin D3-dependent transcription by synthetic LXXLL peptide antagonists that target the activation domains of the vitamin D and retinoid X receptors. J Bone Miner Res 2002;17(12):2196-2205.
61. Pike JW, Pathrose P, Barmina O, Chang CY, McDonnell DP, Yamamoto H, Shevde NK. Synthetic LXXLL peptide antagonize 1, 25-dihydroxyvitamin D3-dependent transcription. J Cell Biochem 2003;88(2):252-258.
62. Lu Y, Yang J, Sega E. Issues related to targeted delivery of proteins and peptides. AAPS J 2006;8(3):E466-478.
63. Geistlinger TR, Guy RK. An inhibitor of the interaction of thyroid hormone receptor beta and glucocorticoid interacting protein 1. J Am Chem Soc 2001;123(7):1525-1526.
64. Geistlinger TR, Guy RK. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J Am Chem Soc 2003;125(23):6852-6853.
65. Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, Chirgadze NY, Wang Y, Burris TP, Spatola AF. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc Natl Acad Sci USA 2003;100(20):11273-11278.
66. Galande AK, Bramlett KS, Burris TP, Wittliff JL, Spatola AF. Thioether side chain cyclization for helical peptide formation: Inhibitors of estrogen receptor-coactivator interactions. J Pept Res 2004;63(3):297-302.
67. Galande AK, Bramlett KS, Trent JO, Burris TP, Wittliff JL, Spatola AF. Potent inhibitors of LXXLL-based protein-protein interactions. Chembiochem 2005;6(11):1991-1998.
68. Carraz M, Zwart W, Phan T, Michalides R, Brunsveld L. Perturbation of estrogen receptor alpha localization with synthetic nona-arginine LXXLL-peptide coactivator binding inhibitors. Chem Biol 2009;16(7):702-711.
69. Phillips C, Roberts LR, Schade M, Bazin R, Bent A, Davies NL, Moore R, Pannifer AD, Pickford AR, Prior SH, Read CM, Scott A, Brown DG, Xu B, Irving SL. Design and structure of stapled peptides binding to estrogen receptors. J Am Chem Soc 2011;133(25):9696-9699.
70. Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci USA 2010;107(32):14093-14098.
71. Arnold SF, Notides AC. An antiestrogen: A phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor. Proc Natl Acad Sci USA 1995;92(16):7475-7479.
72. Yudt MR, Koide S. Preventing estrogen receptor action with dimer-interface peptides. Steroids 2001;66(7):549-558.
73. Chakraborty S, Cole S, Rader N, King C, Rajnarayanan R, Biswas PK. In silico design of peptidic inhibitors targeting estrogen receptor alpha dimer interface. Mol Divers 2012; 16(3):441-451.
74. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001;81(3):1097-1142.
75. Baxter JD, Goede P, Apriletti JW, West BL, Feng W, Mellstrom K, Fletterick RJ, Wagner RL, Kushner PJ, Ribeiro RC, Webb P, Scanlan TS, Nilsson S. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 2002;143(2):517-524.
76. Webb P, Nguyen NH, Chiellini G, Yoshihara HA, Cunha Lima ST, Apriletti JW, Ribeiro RC, Marimuthu A, West BL, Goede P, Mellstrom K, Nilsson S, Kushner PJ, Fletterick RJ, Scanlan TS, Baxter JD. Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol 2002;83(1-5):59-73.
77. Arnold LA, Estebanez-Perpina E, Togashi M, Jouravel N, Shelat A, McReynolds AC, Mar E, Nguyen P, Baxter JD, Fletterick RJ, Webb P, Guy RK. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem 2005;280(52):43048-43055.
78. Arnold LA, Estebanez-Perpina E, Togashi M, Shelat A, Ocasio CA, McReynolds AC, Nguyen P, Baxter JD, Fletterick RJ, Webb P, Guy RK. A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci STKE 2006;2006(341):pl3.
79. Estebanez-Perpina E, Arnold LA, Jouravel N, Togashi M, Blethrow J, Mar E, Nguyen P, Phillips KJ, Baxter JD, Webb P, Guy RK, Fletterick RJ. Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. Mol Endocrinol 2007;21(12):2919-2928.
80. Arnold LA, Kosinski A, Estebanez-Perpina E, Fletterick RJ, Guy RK. Inhibitors of the interaction of a thyroid hormone receptor and coactivators: Preliminary structure-activity relationships. J Med Chem 2007;50(22):5269-5280.
81. Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK. Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem 2009;52(13):3892-3901.
82. Hwang JY, Huang W, Arnold LA, Huang R, Attia RR, Connelly M, Wichterman J, Zhu F, Augustinaite I, Austin CP, Inglese J, Johnson RL, Guy RK. Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone. J Biol Chem 2011;286(14):11895-11908.
83. Johnson RL, Hwang JY, Arnold LA, Huang R, Wichterman J, Augustinaite I, Austin CP, Inglese J, Guy RK, Huang W. A quantitative high-throughput screen identifies novel inhibitors of the interaction of thyroid receptor beta with a peptide of steroid receptor coactivator 2. J Biomol Screen 2011;16(6):618-627.
84. Huang W, Johnson RL, Huang R, Wichterman J, Hwang JY, Guy RK. qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. Probe Reports from the NIH Molecular Libraries Program, 2011/07/08 ed. Bethesda, MD: National Center for Biotechnology Information (US); 2010.
85. Hwang JY, Attia RR, Zhu F, Yang L, Lemoff A, Jeffries C, Connelly MC, Guy RK. Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors. J Med Chem 2012;55(5):2301-2310.
86. Mita Y, Dodo K, Noguchi-Yachide T, Miyachi H, Makishima M, Hashimoto Y, Ishikawa M. LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators. Bioorg Med Chem Lett 2010;20(5):1712-1717.
87. Cummings MD, Schubert C, Parks DJ, Calvo RR, LaFrance LV, Lattanze J, Milkiewicz KL, Lu T. Substituted 1, 4-benzodiazepine-2, 5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction. Chem Biol Drug Des 2006;67(3):201-205.
88. Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA. Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem 2012;55(10):4640-4651.
89. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002;1(4):259-266.
90. Biswas A, Mani S, Redinbo MR, Krasowski MD, Li H, Ekins S. Elucidating the 'Jekyll and Hyde' nature of PXR: The case for discovering antagonists or allosteric antagonists. Pharm Res 2009;26(8):1807-1815.
91. Xue Y, Chao E, Zuercher WJ, Willson TM, Collins JL, Redinbo MR. Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem 2007;15(5):2156-2166.
92. Takeshita A, Taguchi M, Koibuchi N, Ozawa Y. Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 2002;277(36):32453-32458.
93. Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV, Mani S. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007;26(2):258-268.
94. Wang H, Huang H, Li H, Teotico DG, Sinz M, Baker SD, Staudinger J, Kalpana G, Redinbo MR, Mani S. Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res 2007;13(8):2488-2495.
95. Reinhardt TA, Horst RL. Ketoconazole inhibits self-induced metabolism of 1, 25-dihydroxyvitamin D3 and amplifies 1, 25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells. Arch Biochem Biophys 1989;272(2):459-465.
96. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983;71(5):1495-1499.
97. Loose DS, Stover EP, Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest 1983;72(1):404-408.
98. Duret C, Daujat-Chavanieu M, Pascussi JM, Pichard-Garcia L, Balaguer P, Fabre JM, Vilarem MJ, Maurel P, Gerbal-Chaloin S. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: Consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol 2006;70(1):329-339.
99. Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res 1992;24(8):367-370.
100. Jones JO, An WF, Diamond MI. AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol 2009;4(3):199-208.
101. Wang H, Li H, Moore LB, Johnson MD, Maglich JM, Goodwin B, Ittoop OR, Wisely B, Creech K, Parks DJ, Collins JL, Willson TM, Kalpana GV, Venkatesh M, Xie W, Cho SY, Roboz J, Redinbo M, Moore JT, Mani S. The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol 2008;22(4):838-857.
102. Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, Sinz M, Swaan PW, Patel R, Bachmann K. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 2007;72(3):592-603.
103. Ekins S, Kholodovych V, Ai N, Sinz M, Gal J, Gera L, Welsh WJ, Bachmann K, Mani S. Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 2008;74(3):662-672.
104. Rodriguez AL, Tamrazi A, Collins ML, Katzenellenbogen JA. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J Med Chem 2004;47(3):600-611.
105. Parent AA, Gunther JR, Katzenellenbogen JA. Blocking estrogen signaling after the hormone: Pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem 2008;51(20):6512-6530.
106. Gunther JR, Moore TW, Collins ML, Katzenellenbogen JA. Amphipathic benzenes are designed inhibitors of the estrogen receptor alpha/steroid receptor coactivator interaction. ACS Chem Biol 2008;3(5):282-286.
107. Shao D, Berrodin TJ, Manas E, Hauze D, Powers R, Bapat A, Gonder D, Winneker RC, Frail DE. Identification of novel estrogen receptor alpha antagonists. J Steroid Biochem Mol Biol 2004;88(4-5):351-360.
108. LaFrate AL, Gunther JR, Carlson KE, Katzenellenbogen JA. Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor. Bioorg Med Chem 2008;16(23):10075-10084.
109. Zhou HB, Collins ML, Gunther JR, Comninos JS, Katzenellenbogen JA. Bicyclo[2.2.2]octanes: Close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators. Bioorg Med Chem Lett 2007;17(15):4118-4122.
110. Becerril J, Hamilton AD. Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides. Angew Chem Int Ed Engl 2007;46(24):4471-4473.
111. Fletcher S, Hamilton AD. Targeting protein-protein interactions by rational design: Mimicry of protein surfaces. J R Soc Interface 2006;3(7):215-233.
112. Williams AB, Weiser PT, Hanson RN, Gunther JR, Katzenellenbogen JA. Synthesis of biphenyl proteomimetics as estrogen receptor-alpha coactivator binding inhibitors. Org Lett 2009;11(23):5370-5373.
113. Sun A, Moore TW, Gunther JR, Kim MS, Rhoden E, Du Y, Fu H, Snyder JP, Katzenellenbogen JA. Discovering small-molecule estrogen receptor alpha/coactivator binding inhibitors: High-throughput screening, ligand development, and models for enhanced potency. ChemMedChem 2011;6(4):654-666.
114. Wang Y, Chirgadze NY, Briggs SL, Khan S, Jensen EV, Burris TP. A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. Proc Natl Acad Sci USA 2006;103(26):9908-9911.
115. Kojetin DJ, Burris TP, Jensen EV, Khan SA. Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor. Endocr Relat Cancer 2008;15(4):851-870.
116. Mizwicki MT, Keidel D, Bula CM, Bishop JE, Zanello LP, Wurtz JM, Moras D, Norman AW. Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1alpha, 25(OH)2-vitamin D3 signaling. Proc Natl Acad Sci USA 2004;101(35):12876-12881.
117. Gunther JR, Parent AA, Katzenellenbogen JA. Alternative inhibition of androgen receptor signaling: Peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem Biol 2009;4(6):435-440.
118. Estebanez-Perpina E, Arnold LA, Nguyen P, Rodrigues ED, Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, Guy RK, Webb P, Fletterick RJ. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA 2007;104(41):16074-16079.
119. Buzon V, Carbo LR, Estruch SB, Fletterick RJ, Estebanez-Perpina E. A conserved surface on the ligand binding domain of nuclear receptors for allosteric control. Mol Cell Endocrinol 2011;348(2):394-402.
120. Lack NA, Axerio-Cilies P, Tavassoli P, Han FQ, Chan KH, Feau C, LeBlanc E, Guns ET, Guy RK, Rennie PS, Cherkasov A. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J Med Chem 2011;54(24):8563-8573.
121. De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Kim YS, Chen Y, Ning YM, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM, Cox MB. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA 2011;108(29):11878-11883.
122. Grosdidier S, Carbo LR, Buzon V, Brooke G, Nguyen P, Baxter JD, Bevan C, Webb P, Estebanez-Perpina E, Fernandez-Recio J. Allosteric conversation in the androgen receptor ligand-binding domain surfaces. Mol Endocrinol 2012;26(7):1078-1090.
123. Caboni L, Kinsella GK, Blanco F, Fayne D, Jagoe WN, Carr M, Williams DC, Meegan MJ, Lloyd DG. "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: Novel tools for prostate cancer. J Med Chem 2012;55(4):1635-1644.
124. Axerio-Cilies P, Lack NA, Nayana MR, Chan KH, Yeung A, Leblanc E, Guns ES, Rennie PS, Cherkasov A. Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. J Med Chem 2011;54(18):6197-6205.
125. Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, Hann B, Diamond MI. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA 2009;106(17):7233-7238.
126. Jones JO, Diamond MI. A cellular conformation-based screen for androgen receptor inhibitors. ACS Chem Biol 2008;3(7):412-418.
127. Dodou K, Anderson RJ, Small DA, Groundwater PW. Investigations on gossypol: Past and present developments. Expert Opin Investig Drugs 2005;14(11):1419-1434.
128. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial. Breast Cancer Res Treat 2001;66(3):239-248.
129. Hiipakka RA, Zhang HZ, Dai W, Dai Q, Liao S. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 2002;63(6):1165-1176.
130. Song D, Lorenzo B, Reidenberg MM. Inhibition of 11 beta-hydroxysteroid dehydrogenase by gossypol and bioflavonoids. J Lab Clin Med 1992;120(5):792-797.
131. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46(20):4259-4264.
132. York B, O'Malley BW. Steroid receptor coactivator (SRC) family: Masters of systems biology. J Biol Chem 2010;285(50):38743-38750.
133. Walsh CA, Qin L, Tien JC, Young LS, Xu J. The function of steroid receptor coactivator-1 in normal tissues and cancer. Int J Biol Sci 2012;8(4):470-485.
134. Gearhart MD, Dickinson L, Ehley J, Melander C, Dervan PB, Wright PE, Gottesfeld JM. Inhibition of DNA binding by human estrogen-related receptor 2 and estrogen receptor alpha with minor groove binding polyamides. Biochemistry 2005;44(11):4196-4203.
135. Chenoweth DM, Dervan PB. Structural basis for cyclic Py-Im polyamide allosteric inhibition of nuclear receptor binding. J Am Chem Soc 2010;132(41):14521-14529.
136. Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci USA 2007;104(25):10418-10423.
137. Chenoweth DM, Harki DA, Phillips JW, Dose C, Dervan PB. Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J Am Chem Soc 2009;131(20):7182-7188.
138. Punchihewa C, De Alba A, Sidell N, Yang D. XR5944: A potent inhibitor of estrogen receptors. Mol Cancer Ther 2007;6(1):213-219.
139. Whittal RM, Benz CC, Scott G, Semyonov J, Burlingame AL, Baldwin MA. Preferential oxidation of zinc finger 2 in estrogen receptor DNA-binding domain prevents dimerization and, hence, DNA binding. Biochemistry 2000;39(29):8406-8417.
140. Schwabe JW, Chapman L, Finch JT, Rhodes D. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements. Cell 1993;75(3):567-578.
141. Maynard AT, Covell DG. Reactivity of zinc finger cores: Analysis of protein packing and electrostatic screening. J Am Chem Soc 2001;123(6):1047-1058.
142. Wang LH, Yang XY, Zhang X, Mihalic K, Fan YX, Xiao W, Howard OM, Appella E, Maynard AT, Farrar WL. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med 2004;10(1):40-47.
143. Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, Clarke R, Osborne CK, Inman JK, Appella E, Farrar WL. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 2006;10(6):487-499.
144. Mao C, Patterson NM, Cherian MT, Aninye IO, Zhang C, Montoya JB, Cheng J, Putt KS, Hergenrother PJ, Wilson EM, Nardulli AM, Nordeen SK, Shapiro DJ. A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem 2008;283(19):12819-12830.
145. Kretzer NM, Cherian MT, Mao C, Aninye IO, Reynolds PD, Schiff R, Hergenrother PJ, Nordeen SK, Wilson EM, Shapiro DJ. A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}. J Biol Chem 2010;285(53):41863-41873.
146. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem 2003;278(21):19134-19140.
147. Schultz DJ, Wickramasinghe NS, Ivanova MM, Isaacs SM, Dougherty SM, Imbert-Fernandez Y, Cunningham AR, Chen C, Klinge CM. Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation. Mol Cancer Ther 2010;9(3):594-605.
148. Hemshekhar M, Sebastin Santhosh M, Kemparaju K, Girish KS. Emerging roles of anacardic acid and its derivatives: A pharmacological overview. Basic Clin Pharmacol Toxicol 2011.
149. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17(6):535-546.
150. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999;274(12):7777-7783.
151. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277(9):7076-7085.
152. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277(41):38087-38094.
153. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci USA 2007;104(4):1331-1336.
154. Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, Chasanah E, Irianto HE, Soest RV, Andersen RJ. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org Lett 2008;10(21):4947-4950.
155. Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, Park JJ, Tien AH, Fernandez JG, de Voogd NJ, Sadar MD, Andersen RJ. Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: Structure elucidation, synthesis, and biological activity. J Med Chem 2012;55(1):503-514.
156. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011;18(5):R183-R196.
157. Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 2006;281(38):27882-27893.
158. Ottow E, Weinmann, H. Nuclear receptors as drug targets: A historical perspective of modern drug discovery. In: Ottow E, Weinmann, H, Eds. Nuclear Receptors as Drug Targets, Methods and Principles in Medicinal Chemistry. Wiley-VCH; 2008. p 1-23.
159. Norris JD, Joseph JD, Sherk AB, Juzumiene D, Turnbull PS, Rafferty SW, Cui H, Anderson E, Fan D, Dye DA, Deng X, Kazmin D, Chang CY, Willson TM, McDonnell DP. Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol 2009;16(4):452-460.
160. Potashman MH, Duggan ME. Covalent modifiers: An orthogonal approach to drug design. J Med Chem 2009;52(5):1231-1246.